Lipid-Lowering Agents - Brunei Darussalam

  • Brunei Darussalam
  • The Lipid-Lowering Agents market in Brunei Darussalam is expected to see a significant increase in revenue.
  • By 2024, it is projected to reach a total of US$0.25m.
  • This represents a substantial growth opportunity for the country's pharmaceutical industry.
  • Furthermore, the market is anticipated to witness a steady annual growth rate (CAGR 2024-2028) of -1.02%, leading to a market volume of US$0.24m by 2028.
  • In comparison to other countries, United States is projected to generate the highest revenue in the Lipid-Lowering Agents market.
  • In 2024 alone, United States is expected to generate a staggering revenue of US$4,427.00m.
  • This highlights the significance of the Lipid-Lowering Agents market United States and its dominant position in the global pharmaceutical industry.
  • The demand for lipid-lowering agents in Brunei Darussalam is steadily increasing due to the rising prevalence of lifestyle-related diseases.

Key regions: Italy, Japan, France, Brazil, Australia

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The demand for Lipid-Lowering Agents in Brunei Darussalam is on the rise, driven by various factors that are shaping the market.

Customer preferences:
Brunei Darussalam has a growing elderly population, which is susceptible to various chronic diseases such as cardiovascular diseases. This has led to an increasing demand for Lipid-Lowering Agents, which are used to treat high cholesterol levels. Additionally, the growing health consciousness among the younger population is also driving the demand for these drugs.

Trends in the market:
The Lipid-Lowering Agents market in Brunei Darussalam is witnessing a shift towards generic drugs. This is due to the government's efforts to reduce healthcare costs by promoting the use of generic drugs. The generic drugs are cheaper than branded drugs and offer the same therapeutic effect. This has led to an increase in the number of generic drug manufacturers in the country.

Local special circumstances:
Brunei Darussalam has a small population, and the healthcare system is heavily subsidized by the government. This has led to a limited number of private healthcare providers in the country. The government provides free healthcare services to its citizens, which includes the provision of Lipid-Lowering Agents. This has led to a limited market for private healthcare providers in the country.

Underlying macroeconomic factors:
Brunei Darussalam has a stable economy, which is heavily reliant on its oil and gas industry. The government has been investing heavily in the healthcare sector, which has led to the development of modern healthcare infrastructure in the country. This has led to an increase in the availability of Lipid-Lowering Agents in the country. Additionally, the government's efforts to promote the use of generic drugs have led to a reduction in healthcare costs, which has made these drugs more affordable for the population.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Key Players
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)